10x Genomics provides integrated instruments, consumables, and software for analyzing biological systems.

PharosAI and 10x Genomics are partnering to build a large, AI-ready multimodal cancer dataset using the Xenium spatial platform, aiming to advance diagnosis, precision therapies, and drug discovery.

The initiative is backed by 18.9 million pounds from the UK Government’s Research Ventures Catalyst, with additional support from charities and industry partners, and brings together a consortium including King’s College London, Queen Mary University of London, Guy’s and St Thomas’ NHS Foundation Trust, and Barts Health NHS Trust.

PharosAI is a UK consortium comprising King’s College London, Queen Mary University of London, Guy’s and St Thomas’ NHS Foundation Trust, and Barts Health NHS Trust, focused on digitizing and analyzing large-scale cancer tissue samples.

PharosAI’s team size is about 1,306 employees.

The press release includes standard forward-looking statements and disclosures about risks and regulatory considerations, with contact details for investors and media.

Marketscreener is referenced for additional information about 10x Genomics.

Key platforms include the Chromium family for single-cell analysis, Visium for spatial gene expression, and Xenium for in situ analysis to identify cells within tissue context.

Chromium-based assays include Single Cell Gene Expression, Single Cell Gene Expression Flex, Single Cell Immune Profiling, Single Cell ATAC, and Multiome ATAC + Gene Expression, alongside Visium Spatial Gene Expression.

The Chromium X Series, Chromium Connect, and legacy Chromium Controller enable high-throughput analysis, with Visium enabling high-resolution spatial localization and Xenium enabling in situ cell typing and localization.

A central aim is to democratize access to these datasets, enabling broad, secure use by researchers and innovators worldwide.

10x Genomics emphasizes securely sharing AI-ready datasets with a global research community to drive collaboration and innovation.